Literature DB >> 8780735

Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system.

K Lundstrom1, M P Turpin.   

Abstract

Homozygotes for a BalI polymorphism resulting in the Ser9Gly mutation in the human dopamine D3 receptor gene are suggested to display a twofold higher risk of schizophrenia. The cDNAs for this mutant and the wildtype receptor were introduced into the pSFV1C vector and recombinant Semliki Forest virus particles generated. CHO cells infected with SFV-D3 virus resulted in high level expression of recombinant receptor. Double infections with wildtype and Ser9Gly dopamine D3 SFV stocks generated an artificial heterozygote in CHO cells. Receptor binding analysis of several structurally different dopamine D3 ligands showed similar pharmacological properties for all compounds tested except for dopamine and the D3-selective ligand GR99841. A significantly higher dopamine binding affinity for the Ser9Gly homozygote was detected. The heterozygote binding did not differ from the wildtype. However, both the homo- and heterozygote for Ser9Gly showed significantly higher binding activity for GR99841 compared to the D3 wildtype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780735     DOI: 10.1006/bbrc.1996.1296

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  43 in total

Review 1.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

3.  A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor.

Authors:  Freddy Jeanneteau; Benoît Funalot; Joseph Jankovic; Hao Deng; Jean-Pierre Lagarde; Gérard Lucotte; Pierre Sokoloff
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-29       Impact factor: 11.205

4.  The future of pharmacotherapy for schizophrenia.

Authors:  John M Kane; Anil Malhotra
Journal:  World Psychiatry       Date:  2003-06       Impact factor: 49.548

5.  Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings.

Authors:  Saurabh Gupta; Chad A Bousman; Gursharan Chana; Mariana Cherner; Robert K Heaton; Reena Deutsch; Ronald J Ellis; Igor Grant; Ian P Everall
Journal:  J Neurovirol       Date:  2011-04-14       Impact factor: 2.643

Review 6.  From dopaminergic genes to psychiatric disorders.

Authors:  Janet Hoenicka; María Aragüés; Guillermo Ponce; Roberto Rodríguez-Jiménez; Miguel A Jiménez-Arriero; Tomás Palomo
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 7.  Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics.

Authors:  Wolfgang Maier; Astrid Zobel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 8.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

9.  Hypomania and saccadic changes in Parkinson's disease: influence of D2 and D3 dopaminergic signalling.

Authors:  Esther A Pelzer; Barbara Dillenburger; Sophie Grundmann; Vladimir Iliaev; Sophie Aschenberg; Corina Melzer; Martin Hess; Gereon R Fink; Carsten Eggers; Marc Tittgemeyer; Lars Timmermann
Journal:  NPJ Parkinsons Dis       Date:  2020-01-17

10.  Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.

Authors:  Maurits E L Arbouw; Kris L L Movig; Toine C G Egberts; Petra J E Poels; Jeroen P P van Vugt; Judith A M Wessels; R J H M van der Straaten; Cees Neef; Henk-Jan Guchelaar
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.